Envirotainer, the global market leader in secure cold chain solutions for shipment of pharmaceuticals, has extensively expanded its production site in Rosersberg, Sweden in Europe continent. This site is the largest in the world in terms of output, able to build more units each year than any other. It’s also been designed to allow further expansion in the future.

Peter Gisel-Ekdahl, Envirotainer CEO, opened the expanded facility this month and thanked employees for working tirelessly to boost production, meeting the needs of the pharmaceutical industry now and in the future.

Sofie Nordhamren, Head of Quality Control and Production Manager at Envirotainer said, “The demand for our services has been sky-high since the start of the pandemic. The need to safely transport pharmaceuticals while minimising wasted space in precious air cargo has increased dramatically.

If we talk about Asia, here the company has opened a new CryoSure® station in Singapore.

The CryoSure® station in Singapore sits near one of the largest airports in the world for international cargo traffic and a major hub for Asia and Pacific (APAC). This puts -70°C cryogenic shipping within reach of the fastest growing region in the pharmaceutical logistics market.

The new site complements Envirotainer’s existing presence in Singapore, ensures high global service levels and allows express orders throughout APAC.

With this new addition to Envirotainer’s broad global network, customers will benefit from more efficient logistics. It not only improves the offering for customers in terms of speed and availability, but also sustainability.

CryoSure® is the most sustainable solution of its type on the market. The reusable dewars are noticeably less bulky than others and have two to three times better weight to volume efficiency compared to existing dry-ice boxes and liquid nitrogen (LN₂) solutions. This translates into both significantly reduced transportation costs, as well as significantly lower carbon emissions.

With CryoSure® now available on a global scale, it will be possible to ensure vital treatments can be where and when needed quickly in most of Europe, North America and Asia. Expansion of the network will continue.